ポスターダウンロード_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Pharmacology service

ゲノム編集

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

資料ダウンロード

ポスターダウンロード

ニュース & PR

世界に通用する跳躍

ニュースリリース

キャンペーン一覧

ウェビナー

発表論文一覧

資料ダウンロード

ポスターダウンロード

製品資料ダウンロード

AACR 2023: 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity

AACR 2023: *Novel Preclinical Candidates Targeting B7-H3, 6B5 and 10F7, Are Suitable for Development Into Various Drug Modalities

AACR 2023: BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice

AACR 2023: D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice

AACR 2023: A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies

AACR 2023: B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A

AACR 2023: Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages

AACR 2023: Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics

AACR 2023: In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice

1 … 4 5 6 7 8 … 11